Litcius/Paper detail

Fixed Duration Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma-Results of the Ascent Trial

Shaji Kumar, Melissa Alsina, Betsy LaPlant, Ashraf Badros, Al‐Ola Abdallah, Rafat Abonour, Erik Asmus, Binod Dhakal, Cara A. Rosenbaum, Daniel Egan, Manisha Bhutani, Andrzej Jakubowiak, Brian G.M. Durie

2022Blood40 citationsDOI

Topics & Concepts

DaratumumabCarfilzomibLenalidomideMultiple myelomaPomalidomideMedicineDexamethasoneOncologyInternal medicineThalidomideMultiple Myeloma Research and Treatments
Fixed Duration Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma-Results of the Ascent Trial | Litcius